Performance of Indirect Adherence Measures for Daily Oral Pre-exposure Prophylaxis for HIV Among Adolescent Men Who Have Sex with Men and Transgender Women in Brazil

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2024 Dec 31

PMID 39739641

Authors

Diana Zeballos

Laio Magno

Fabiane Soares

Jony Arrais Pinto Junior

Leila Amorim

Dirceu Greco

Alexandre Grangeiro

Ines Dourado

Affiliations

Soon will be listed here.

Abstract

Background: Consistent monitoring of PrEP adherence with accurate measurement tools at point-of-care could greatly contribute to reaching adolescents with poor adherence. We aimed to assess the performance of indirect adherence measures to oral PrEP among adolescent men who have sex with men (AMSM) and adolescent transgender women (ATGW).

Methods: PrEP15-19 is a prospective, multicenter, PrEP demonstration cohort study that includes AMSM and ATGW aged 15-19 in three Brazilian cities. A diagnostic accuracy study was conducted using tenofovir-diphosphate (TFV-DP) concentrations in dried blood spots as the reference standard, along with three index tests: medication possession ratio (MPR), pill count, and self-report. We calculated the area under the curve (AUC) for protective TFV-DP levels (≥800 fmol/punch) and sensitivity (SE) and specificity (SP) for established cutoff points.

Results: We included 302 samples from 188 participants. Most of participants were AMSM (78.7%), aged 18-19 years (80.3%), and non-whites (72.9%). The AUC was 0.59 for MPR, 0.69 for pill count, and 0.75 for self-report. When combining MPR and self-report, the AUC increased to 0.77. Sensitivity was high for the cutoff points identified by the Youden index, 80% for MPR, 92% for self-report, and 97% for pill count. However, specificities were low 40%, 46%, and 38%, respectively.

Conclusions: Indirect measures were able to discriminate adolescents with good adherence. However, their performance in identifying those with low adherence might be limited, suggesting that it is necessary to initiate adherence interventions when there is no evidence of perfect adherence. Combining measures can provide wider information on adherence.

References

Williams A, Amico K, Bova C, Womack J . A proposal for quality standards for measuring medication adherence in research. AIDS Behav. 2012; 17(1):284-97. PMC: 3434290. DOI: 10.1007/s10461-012-0172-7. View

Anderson P, Liu A, Castillo-Mancilla J, Gardner E, Seifert S, McHugh C . Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy. Antimicrob Agents Chemother. 2017; 62(1). PMC: 5740314. DOI: 10.1128/AAC.01710-17. View

Obuchowski N . Nonparametric analysis of clustered ROC curve data. Biometrics. 1997; 53(2):567-78. View

Haberer J, Mugo N, Bukusi E, Ngure K, Kiptinness C, Oware K . Understanding Pre-Exposure Prophylaxis Adherence in Young Women in Kenya. J Acquir Immune Defic Syndr. 2022; 89(3):251-260. PMC: 8826617. DOI: 10.1097/QAI.0000000000002876. View

Hosek S, Rudy B, Landovitz R, Kapogiannis B, Siberry G, Rutledge B . An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM. J Acquir Immune Defic Syndr. 2016; 74(1):21-29. PMC: 5140725. DOI: 10.1097/QAI.0000000000001179. View

Hajian-Tilaki K . Sample size estimation in diagnostic test studies of biomedical informatics. J Biomed Inform. 2014; 48:193-204. DOI: 10.1016/j.jbi.2014.02.013. View

Abaasa A, Hendrix C, Gandhi M, Anderson P, Kamali A, Kibengo F . Utility of Different Adherence Measures for PrEP: Patterns and Incremental Value. AIDS Behav. 2017; 22(4):1165-1173. PMC: 5878836. DOI: 10.1007/s10461-017-1951-y. View

Leech A, Biancarelli D, Aaron E, Miller E, Coleman J, Anderson P . HIV Pre-Exposure Prophylaxis for Conception Among HIV Serodiscordant Couples in the United States: A Cohort Study. AIDS Patient Care STDS. 2020; 34(7):295-302. PMC: 7370981. DOI: 10.1089/apc.2020.0005. View

Musinguzi N, Muganzi C, Boum 2nd Y, Ronald A, Marzinke M, Hendrix C . Comparison of subjective and objective adherence measures for preexposure prophylaxis against HIV infection among serodiscordant couples in East Africa. AIDS. 2016; 30(7):1121-9. DOI: 10.1097/QAD.0000000000001024. View

10.

Blumenthal J, Pasipanodya E, Jain S, Sun S, Ellorin E, Morris S . Comparing Self-Report Pre-Exposure Prophylaxis Adherence Questions to Pharmacologic Measures of Recent and Cumulative Pre-Exposure Prophylaxis Exposure. Front Pharmacol. 2019; 10:721. PMC: 6624646. DOI: 10.3389/fphar.2019.00721. View

11.

Hajian-Tilaki K . The choice of methods in determining the optimal cut-off value for quantitative diagnostic test evaluation. Stat Methods Med Res. 2017; 27(8):2374-2383. DOI: 10.1177/0962280216680383. View

12.

Grant R, Anderson P, McMahan V, Liu A, Amico K, Mehrotra M . Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014; 14(9):820-9. PMC: 6107918. DOI: 10.1016/S1473-3099(14)70847-3. View

13.

Baker Z, Javanbakht M, Mierzwa S, Pavel C, Lally M, Zimet G . Predictors of Over-Reporting HIV Pre-exposure Prophylaxis (PrEP) Adherence Among Young Men Who Have Sex With Men (YMSM) in Self-Reported Versus Biomarker Data. AIDS Behav. 2017; 22(4):1174-1183. PMC: 6038811. DOI: 10.1007/s10461-017-1958-4. View

14.

Hannaford A, Arens Y, Koenig H . Real-Time Monitoring and Point-of-Care Testing: A Review of the Current Landscape of PrEP Adherence Monitoring. Patient Prefer Adherence. 2021; 15:259-269. PMC: 7873020. DOI: 10.2147/PPA.S248696. View

15.

Stirratt M, Dunbar-Jacob J, Crane H, Simoni J, Czajkowski S, Hilliard M . Self-report measures of medication adherence behavior: recommendations on optimal use. Transl Behav Med. 2015; 5(4):470-82. PMC: 4656225. DOI: 10.1007/s13142-015-0315-2. View

16.

Wheeler D, Fields S, Beauchamp G, Chen Y, Emel L, Hightow-Weidman L . Pre-exposure prophylaxis initiation and adherence among Black men who have sex with men (MSM) in three US cities: results from the HPTN 073 study. J Int AIDS Soc. 2019; 22(2):e25223. PMC: 6376611. DOI: 10.1002/jia2.25223. View

17.

Osterberg L, Blaschke T . Adherence to medication. N Engl J Med. 2005; 353(5):487-97. DOI: 10.1056/NEJMra050100. View

18.

Dourado I, Magno L, Greco D, Zucchi E, Ferraz D, Westin M . Interdisciplinarity in HIV prevention research: the experience of the PrEP1519 study protocol among adolescent MSM and TGW in Brazil. Cad Saude Publica. 2023; 39Suppl 1(Suppl 1):e00143221. DOI: 10.1590/0102-311XEN143221. View

19.

Marins L, Torres T, Leite I, Moreira R, Luz P, Hoagland B . Performance of HIV pre-exposure prophylaxis indirect adherence measures among men who have sex with men and transgender women: Results from the PrEP Brasil Study. PLoS One. 2019; 14(8):e0221281. PMC: 6701758. DOI: 10.1371/journal.pone.0221281. View

20.

Schaefer R, Schmidt H, Ravasi G, Mozalevskis A, Rewari B, Lule F . Adoption of guidelines on and use of oral pre-exposure prophylaxis: a global summary and forecasting study. Lancet HIV. 2021; 8(8):e502-e510. PMC: 8332196. DOI: 10.1016/S2352-3018(21)00127-2. View